APSR2026-254

Yes
Late-Breaking
Submitted
Poster Presentation
 
AP09-010
P136
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1216232-46904-AP09-010_SEBASTIAN_433502.pdf
Format: PDF Only
14. Respiratory Structure and Function
4

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Marie Elaine Sebastian * Zamboanga City Medical Centee Internal Medicine Zamboanga City Philippines
Shareefa - Huda Mandangan - Zamboanga City Medical Centee Adult Pulmonologist and Sleep Medicine Zamboanga City Philippines
Eric Galo - Zamboanga City Medical Centee Adult Pulmonologist Zamboanga City Philippines
Annie Rose Ammar - Zamboanga City Medical Centee Adult Rheumatologist Zamboanga City Philippines
 
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
Marie Elaine
Sebastian
sagososagososagoso@gmail.com
+63+63+63+639688866006
31-40
Philippines
Case Report
Cystic Bronchiectasis as a Pulmonary Manifestation of primary Sjogren Syndrome: Structured Physiologic and Radiologic Reasoning in a Limited – Resource Care
Maximum 25 words
Abstract Content
 
 
 
 
Pulmonary manifestations of primary Sjogren syndrome include both interstitial lung disease and airway – centered disease. Reduced vital capacity with parenchymal abnormalities may be misinterpreted as restrictive lung disease particularly when lung volume are unavailable. Accurate classification requires integration of spirometry and high – resolution computed tomography (HRCT) findings. This case highlights structured diagnostic reasoning to distinguish airway – predominant disease from interstitial involvement.
A 50 – year – old non-smoking female presented with progressive exertional dyspnea and repeated admissions for presumed chronic obstructive pulmonary lung disease despite minimal bronchodilator response. Longstanding sicca symptoms and anti – SSA antibody positivity confirmed primary Sjogren syndrome. Spirometry showed moderate airflow obstruction (FEV1 57% predicted; FEV1/FVC ratio 61%) with reduced forced vital capacity (78% predicted), raising concern of mixed ventilatory impairment. Slow vital capacity was lower than FVC, consistent with air trapping. Maximum voluntary ventilation was proportionate to FEV1 excluding neuromuscular limitation. Lung capacity and diffusing capacity were unavailable. HRCT with ILD protocol demonstrated bilateral lower lobe cystic bronchiectasis predominance, mosaic attenuation with expiratory air trapping, patchy groundglass opacities and thin-walled cysts (Figure 1) without honeycombing architectural distortion. ATS classification categorized an alternative diagnosis rather than fibrosing interstitial lung disease. CTPA showed dilated pulmonary arteries dilation. Multidisciplinary integration concluded that airway – predominant cystic bronchiectasis represented the dominant pulmonary phenotype.
This case illustrates a critical diagnostic principle that reduced vital capacity does not necessarily indicate restrictive interstitial disease. In obstructive lung disease, air trapping may reduce measured vital capacity and mimic restriction when lung volumes are unavailable. Comparison of slow and forced vital capacities, along with assessment of maximum voluntary ventilation proportionality can identify pseudo – restriction. Radiologically, the presence of ground – glass opacities and parenchymal cysts broadened the differential diagnosis to include lymphocytic interstitial pneumonia, a recognized pulmonary manifestation of primary Sjogren syndrome. However, absence of fibrotic architectural distortion and application of ATS classification favored airway – centered disease rather than a fibrosing interstitial processes. Although structured physiologic and radiologic evaluation support airway – predominant involvement, interstitial manifestations related to the underlying autoimmune disease cannot be excluded. Given the established diagnosis of pSS, patient remains under longitudinal surveillance, with immunomodulatory therapy guided by systemic disease activity and evidence of pulmonary progression.
 
 
Yes
Yes
https://storage.unitedwebnetwork.com/files/1285/1216232-37089-Figure1_374115.jpg
JPG or JPEG or PNG format ONLY
Primary Sjogren syndrome, bronchiectasis, phenotype classification
maximum 3 keywords and no abbreviations, separated by commas
The authors declare that there are no conflicts of interest relevant to this case report. The authors have no financial relationships with commercial entities that could be perceived as influencing the content of this manuscript. Written informed consent was obtained from the patient for this case report. Identifying information has been omitted to preserve patient confidentiality.
360